Ysios Capital

#PortfolioNews I Our #quoted #portfolio company Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced Phase 2 #ClinicalTrial of #Lorundrostat for #ObstructiveSleepApnea in Patients with #Hypertension 👉 https://buff.ly/40bQ8ax 🔬 The FDA - La Administración de Alimentos y Medicamentos has cleared the company’s IND application for a Phase 2 trial of lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. 🎯 This expands lorundrostat’s potential in aldosterone-driven diseases, with the trial set to begin in Q1 2025. 🌎 Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality Excited to watch Mineralys continue to innovate in healthcare! #vc #NasdaqListed #ClinicalTrials #Innovation #PrecisionMedicine #HealthcareInnovation

#PortfolioNews I Our #portfolio company Anaconda BioMed has named Trent Reutiman as its new CEO. Based in the San Francisco Bay Area, Trent will drive the company's U.S. expansion and lead the regulatory push for its groundbreaking ANA5 Advanced Neurovascular Access™ technology. Thanks to former CEO Francois Salmon, who now transitions to Board Chairman. Big things ahead for Anaconda! 🚀 👉 https://buff.ly/3CdrHkZ #LeadershipChange #MedTech #Neurovascular #Innovation #CEO #Thrombectomy #StrokeTreatment #Healthcare #MedicalDevices #NextGenMedTech

#SeasonsGreetings I 🎄 𝗔𝘀 𝘄𝗲 𝘄𝗿𝗮𝗽 𝘂𝗽 𝟮𝟬𝟮𝟰, 𝘄𝗲 𝗿𝗲𝗳𝗹𝗲𝗰𝘁 𝗼𝗻 𝗮 𝘆𝗲𝗮𝗿 𝗼𝗳 𝗴𝗿𝗲𝗮𝘁 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗮𝘁 𝗬𝘀𝗶𝗼𝘀 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 💪 From supporting #groundbreaking #innovations in #lifeSciences to launching the Telescope Biotech Fund, we’ve worked tirelessly to drive impactful advancements in #health and #biotech. This year, we also took a significant step in our #ESG journey by publishing our first report, reaffirming our commitment to #sustainability and responsible investment. We’re proud of what we’ve achieved and excited for what’s to come. Here’s to an even brighter 2025, filled with new opportunities and success! 🥂 #Innovation #VC #progress #impactinvestment

#PortfolioNews I We’re proud to celebrate a major achievement from our #portfolio company, Kynexis! 👉 https://buff.ly/3DgH9go 🔬 Their Phase 1 study of #KYN5356, a first-in-class small molecule inhibitor of KAT-II, a key enzyme in the #kynurenine pathway implicated in #Schizophrenia, has yielded #positive topline results. This represents an important step toward addressing #CognitiveImpairment in schizophrenia patients. Study Highlights: ✅ Excellent safety profile and strong central nervous system penetration. ✅ Clear evidence of target engagement through biomarkers and EEG activity. ✅ Early indications of cognitive improvement in patients. 🎯 With these promising results, Kynexis is gearing up to start its first-in-patient trial in 2025. This milestone underscores the potential of precision medicine in tackling complex brain diseases. 👏 Congratulations to the Kynexis team for this exceptional achievement! Together, we’re advancing innovative therapies for debilitating brain diseases. #LifeSciences #Biotech #YsiosPortfolio #BrainDiseases #PrecisionMedicine #Biotechnology #Neuroscience #BrainHealth #CNS #Neuropsychiatry #ClinicalTrials #DrugDevelopment #vc #Innovation

#Fund I 🤝 𝙔𝙨𝙞𝙤𝙨 𝘾𝙖𝙥𝙞𝙩𝙖𝙡 𝙮 𝘼𝙣𝙙𝙗𝙖𝙣𝙠 𝙨𝙚 𝙖𝙡í𝙖𝙣 𝙥𝙖𝙧𝙖 𝙡𝙖𝙣𝙯𝙖𝙧 𝙏𝙚𝙡𝙚𝙨𝙘𝙤𝙥𝙚 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙁𝙪𝙣𝙙 📈 Nos alegra anunciar el lanzamiento de 𝗧𝗲𝗹𝗲𝘀𝗰𝗼𝗽𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗙𝘂𝗻𝗱, un fondo gestionado por Andbank , que contará con nuestro asesoramiento especializado. 🎯 Telescope es un fondo con vocación global que invertirá en compañías cotizadas del sector biomédico, principalmente en #Nasdaq y #NYSE. Nuestro rol como asesores se centra en aportar nuestra experiencia para identificar compañías con alto potencial de crecimiento, impulsadas por la #innovación y el desarrollo de nuevos tratamientos que puedan transformar la vida de los pacientes. 🌎 En Ysios Capital seguimos apostando por la #biotecnología como motor de cambio en la #medicina del #futuro. #Biotecnología #Inversión #Innovación #YsiosCapital #ImpactoPositivo

Ayer tuvimos el placer de participar en la jornada "Retos del acceso a los mercados de capitales en el Sector de Ciencias de la Vida", organizada por Science & Innovation Link Office (SILO) Nuestro partner, Jordi Xiol, y nuestra general partner, Cristina Garmendia Mendizábal compartieron ideas y reflexiones sobre los retos de #financiación e #inversión que enfrentan las empresas del sector en su desarrollo. Fue un privilegio formar parte de este espacio de diálogo junto a destacados expertos del sector. Gracias a SILO por contar con nosotros y al resto de organizadores Bird & Bird, BME | Bolsas y Mercados Españoles y AseBio - Asociación Española de Bioempresas por hacerlo posible. #CienciasDeLaVida #Inversión #Innovación

#PortfolioNews I We are excited to share that SpliceBio has received #FDA IND clearance for SB-007, the only IND-cleared, clinical-stage therapeutic addressing the root cause of #Stargardtdisease with the potential to treat all patients across all ABCA4 mutations 👏 Full details 👉 https://buff.ly/3Da7dtE ✅ First-ever IND clearance for a Protein Splicing #genetherapy. 🔬Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease 🎯 As the first-ever IND for a Protein Splicing gene therapy, it is a huge step forward to demonstrate the potential of this new therapeutic modality to address diseases caused by mutations in large genes. Congratulations to Miquel Vila-Perello and the whole SpliceBio team on this major milestone! #YsiosCapital #SpliceBio #FDAApproval #SB007 #StargardtDisease #GeneTherapy #ProteinSplicing #Ophthalmology #Biotech #LifeSciences #HealthcareInnovation

#PortfolioNews I Thrilled to share an important milestone from our #portfolio company, Minoryx Therapeutics! 👏 📢 Their pivotal #NEXUS trial evaluating #leriglitazone in pediatric patients with cerebral #Adrenoleukodystrophy (#cALD) has delivered #positive results. Full details 👉 https://buff.ly/3ZADH85 🔬 NEXUS #Trial Highlights: Designed to assess the #efficacy and #safety of once-daily oral leriglitazone for #pediatric cALD patients. ✅ The trial has been successfully completed, with the #primary #endpoint met. ✅ Leriglitazone demonstrated a strong safety profile, being well tolerated in all participants with no treatment-related serious adverse events reported. 🎯 Building on these results, Minoryx plans to file a Marketing Authorization Application (MAA) to the European Medicines Agency for leriglitazone in pediatric and adult #cALD patients by mid-2025. 🚀 This marks a significant step forward in transforming treatment options for rare neurodegenerative diseases. Congratulations to the entire Minoryx Therapeutics team led by Marc Martinell for this exceptional achievement! #Biotech #LifeSciences #RareDiseases #Innovation #Spain #BioRegion #CNS

🌍 𝗬𝘀𝗶𝗼𝘀 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝘀 𝘁𝗵𝗲 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 #𝗘𝗦𝗚 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 🧬 At Ysios Capital, under the leadership of our #Partner and Head of ESG, Paula Olazábal, we are committed to driving positive change in the Life Sciences investment community. That’s why we are proud to support the 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗘𝗦𝗚 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗣𝗿𝗼𝗷𝗲𝗰𝘁, a groundbreaking initiative shaping sustainability standards within our industry. 🤝 With the participation of 23 leading Life Sciences investors, this collaborative effort has released its 𝟮𝟬𝟮𝟱 𝗕𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝗻𝗮𝗶𝗿𝗲. This tool is designed to streamline ESG data collection for portfolio companies and investors, aligning with key regulations like the 𝘚𝘶𝘴𝘵𝘢𝘪𝘯𝘢𝘣𝘭𝘦 𝘍𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘋𝘪𝘴𝘤𝘭𝘰𝘴𝘶𝘳𝘦 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 (𝘚𝘍𝘋𝘙) and the 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘚𝘶𝘴𝘵𝘢𝘪𝘯𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘙𝘦𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘚𝘵𝘢𝘯𝘥𝘢𝘳𝘥𝘴 (𝘌𝘚𝘙𝘚). 📑 The updated questionnaire reflects the latest ESG developments and ensures practicality and relevance for the Life Sciences sector. 📢 We invite you to learn more and download the questionnaire here 🔗 https://buff.ly/4fUWC4i This initiative remains open to new participants eager to join this collaborative effort to shape the future of sustainable investing in Life Sciences. If you are interested in joining the project please get in touch with Paula Olazábal. 🚀 We’re excited to continue our contributions and collaborations through this important project. Thank you, Paula, for your dedication to advancing ESG practices at Ysios and beyond. 💪 #Sustainability #ESG #LifeSciences #VentureCapital #SocialResponsibility #Collaboration

🎙#Podcast I 🚨La #obesidad: la gran epidemia del siglo XXI  🌐 🆕 En el nuevo episodio de📡PÍLDORAS DE BIOTECH 💊 Enric Miquel de Pharma New Talent y Jordi Xiol exploran uno de los temas más candentes en la farmacología moderna: la obesidad y su tratamiento. 🔴 De un 15% en 1980 a un 43% en 2023 en EE. UU. 🔴 En Europa, de un 9% a un 23%. 📊 IMC > 30: Hablamos de una auténtica crisis global que no solo afecta la salud individual, sino que representa un enorme desafío para los sistemas sanitarios de todo el mundo. 🎯 Desde los revolucionarios agonistas de GLP-1 hasta la emergente #Amilina como nueva diana terapéutica, analizamos el impacto de estos avances en la salud pública y el sector farmacéutico. 🚀 ¡No te lo pierdas! Dale play ahora y explora cómo la innovación farmacéutica está redefiniendo el futuro de la obesidad y sus tratamientos. 👉 https://spoti.fi/49ffici 🛋️ Temas destacados: [0:15]: Obesidad y diabetes: hot topic. [1:00]: Agonistas de GLP-1 la revolución inesperada [3:02]: Mortalidad en obesidad: más allá de un tratamiento cosmético. [4:03]: La obesidad como la gran epidemia del siglo XXI. [5:30]: Cambios de paradigma en el tratamiento de la obesidad: del estigma a la revolución. [7:03]: Novo Nordisk: la empresa más valiosa de Europa. [8:12]: Problemas de tolerancia y adherencia en los tratamientos actuales. [9:13]: Obesidad como enfermedad crónica: efecto rebote. [10:17]: Amilina: la nueva diana terapéutica en obesidad. [12:05]: Diferencias clave entre Amilina y GLP-1: de la falta de apetito a la saciedad. [15:07]: Estrategias de innovación: combinaciones y nuevos desarrollos de Amilina. [17:31]: Zealand Pharma: avances clínicos y rondas de financiación en Amilina. [19:02]: Canibalización interna en farma: estrategias frente al vencimiento de patentes. [21:13]: Nuevos players en la carrera: Zealand Pharma (de nuevo daneses) [23:12]: Desafíos en el desarrollo y comercialización de nuevos tratamientos. #YsiosPodcast #BiotechPillsWithJordi #IndustriaFarmacéutica #VentureCapital #SaludGlobal #Innovación #Biotech #Pharma #SaludPública